Sickle Cell Disease Treatment Market Size, Share and Forecast 2019-2025

1. The development and innovation in the sickle cell disease treatment are encouraging the growth of the sickle cell disease treatment market. For instance, stem cell transplantation is the only potential treatment to cure sickle cell disease treatment. In this treatment, the old stem cell is replaced with the healthy stem cell in bone marrow donated by a matching donor. Bone marrow is the source of new red blood cells, by the transplantation of stem cell the new flexible and round-shaped healthy red blood cells are produced in order to cure the sickle cell disease treatment. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/sickle-cell-disease- treatment-market Various medications are approved in order to treat and cure sickle cell disease treatment which is creating enormous opportunities for the sickle cell disease treatment market. For instance, in November 2019, the US FDA approved the Oxybryta (voxelotor) a therapeutic treatment for the treatment of sickle cell disease which is developed by Global Blood Therapeutics. The therapy is developed with the aim to provide prevention from the sticking of hemoglobin in order to smooth the flow of red blood cells in blood vessels to the organs maintaining the flexible shape of the red blood cell. Browse for Full Report at: https://www.omrglobal.com/industry-reports/sickle-cell-disease- treatment-market In November 2019, Novartis AG granted the approval of Adakveo (Crizanluzumab) by the FDA. Adakveo has an antibody that is used to block one of the proteins in the endothelial cells of the blood vessels. This antibody prevents the protein from binding the sickle cells which in turn used to reduce the pain associated with the sickle cell because of blockage in the red blood cells. The major symptom of sickle cell disease is the pain associated with sickle cell and many pain-relieving medications are prescribed in order to cure the acute pain in the patients. In November 2017, Micelle Bio Pharma, Inc. granted the approval of sickle cell disease treatment Altemia and found many successful results in the reduction of vaso-occlusive crises (VOCs). Altemia is a drug containing a mixture of lipids formulated using advanced lipid

2. technology (ALT) and is primarily designed for the treatment of sickle cell diseases.The drug has the ability to increase the fluidity of red blood cells and treatment of disease by reducing blood cell adhesion, blood cell hemolysis and inflammation. A new CRISPER (Clustered regularly inter spaced short palindromic repeats) technology is used to replace the stem cell in order to produce a high level of fetal hemoglobin and replacing it with the damaged hemoglobin in the red blood cell. Therefore the emerging developments in the treatment options and drugs will be anticipated to boost the sickle cell disease market. Sickle Cell Disease Treatment Market Segmentation By Drug Type •Medication •Blood Transfusions •Bone-Marrow Transplant By Disease •Sickle Cell Anemia •Sickle Hemoglobin C Disease •Sickle Beta Thalassemia •Sickle Beta-Zero Thalassemia Sickle Cell Disease Treatment Market – Segment by Region North America •The US •Canada Europe •Germany

3. •UK •France •Spain •Italy •Rest of Europe Asia-Pacific •China •Japan •India •Rest of Asia-Pacific Rest of the World For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/sickle-cell-disease-treatment-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404